Kevin Litchfield

13.5k total citations · 1 hit paper
53 papers, 2.1k citations indexed

About

Kevin Litchfield is a scholar working on Molecular Biology, Oncology and Cancer Research. According to data from OpenAlex, Kevin Litchfield has authored 53 papers receiving a total of 2.1k indexed citations (citations by other indexed papers that have themselves been cited), including 24 papers in Molecular Biology, 22 papers in Oncology and 17 papers in Cancer Research. Recurrent topics in Kevin Litchfield's work include Cancer Immunotherapy and Biomarkers (18 papers), Cancer Genomics and Diagnostics (16 papers) and Testicular diseases and treatments (14 papers). Kevin Litchfield is often cited by papers focused on Cancer Immunotherapy and Biomarkers (18 papers), Cancer Genomics and Diagnostics (16 papers) and Testicular diseases and treatments (14 papers). Kevin Litchfield collaborates with scholars based in United Kingdom, United States and Sweden. Kevin Litchfield's co-authors include Charles Swanton, Clare Turnbull, Samra Turajlic, Roberto Vendramin, Richard S. Houlston, Sergio A. Quezada, James L. Reading, James Larkin, Hang Xu and Yien Ning Sophia Wong and has published in prestigious journals such as Nature, Journal of Clinical Investigation and Nature Communications.

In The Last Decade

Kevin Litchfield

48 papers receiving 2.1k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Insertion-and-deletion-derived tumour-specific neoantigens and the immunogenic phenotype: a pan-cancer analysis

2017 662 citations Samra Turajlic, Kevin Litchfield et al. profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Kevin Litchfield United Kingdom	23	900	885	585	509	458	53	2.1k
Julio C. Ricarte‐Filho United States	14	832 0.9×	952 1.1×	265 0.5×	356 0.7×	242 0.5×	29	3.1k
Douglas I. Lin United States	26	1.4k 1.5×	1.0k 1.2×	417 0.7×	916 1.8×	125 0.3×	112	2.6k
Lorenza Pecciarini Italy	17	836 0.9×	860 1.0×	349 0.6×	356 0.7×	173 0.4×	42	2.1k
Joshua Armenia United States	18	841 0.9×	680 0.8×	512 0.9×	412 0.8×	153 0.3×	35	1.6k
Cinzia Lavarino Spain	24	986 1.1×	713 0.8×	408 0.7×	336 0.7×	98 0.2×	73	2.0k
So Young Kang South Korea	29	714 0.8×	895 1.0×	532 0.9×	634 1.2×	203 0.4×	92	2.1k
Jeremy Clark United Kingdom	25	1.3k 1.5×	581 0.7×	645 1.1×	1.1k 2.2×	122 0.3×	42	2.5k
Haeyoun Kang South Korea	21	1.0k 1.1×	695 0.8×	1.0k 1.8×	254 0.5×	138 0.3×	59	2.1k
Susanna Cappia Italy	24	651 0.7×	766 0.9×	363 0.6×	748 1.5×	293 0.6×	56	2.0k
Anita Wolfer Switzerland	13	1.3k 1.5×	690 0.8×	352 0.6×	127 0.2×	454 1.0×	32	2.2k

Countries citing papers authored by Kevin Litchfield

Since Specialization

Citations

This map shows the geographic impact of Kevin Litchfield's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Kevin Litchfield with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Kevin Litchfield more than expected).

Fields of papers citing papers by Kevin Litchfield

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Kevin Litchfield. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Kevin Litchfield. The network helps show where Kevin Litchfield may publish in the future.

Co-authorship network of co-authors of Kevin Litchfield

This figure shows the co-authorship network connecting the top 25 collaborators of Kevin Litchfield. A scholar is included among the top collaborators of Kevin Litchfield based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Kevin Litchfield. Kevin Litchfield is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Boumelha, Jesse, Nourdine Bah, Hongui Cha, et al.. (2024). CRISPR–Cas9 Screening Identifies KRAS-Induced COX2 as a Driver of Immunotherapy Resistance in Lung Cancer. Cancer Research. 84(14). 2231–2246. 10 indexed citations

Puttick, Clare, Michelle Leung, Felipe Gálvez‐Cancino, et al.. (2024). MHC Hammer reveals genetic and non-genetic HLA disruption in cancer evolution. Nature Genetics. 56(10). 2121–2131. 15 indexed citations

Qian, Danwen, Krupa Thakkar, Marcellus Augustine, et al.. (2024). A pan-cancer single-cell RNA-seq atlas of intratumoral B cells. Cancer Cell. 42(10). 1784–1797.e4. 16 indexed citations

Roerden, Malte, Andrea Castro, Yufei Cui, et al.. (2024). Neoantigen architectures define immunogenicity and drive immune evasion of tumors with heterogenous neoantigen expression. Journal for ImmunoTherapy of Cancer. 12(11). e010249–e010249. 8 indexed citations

Vendramin, Roberto, Danwen Qian, Yue Zhao, et al.. (2024). Abstract 5625: Targeting the nonsense mediated mRNA decay pathway to prevent the degradation of highly immunogenic frameshift mutated transcripts. Cancer Research. 84(6_Supplement). 5625–5625. 1 indexed citations

Murai, Jun, et al.. (2024). Using a pan-cancer atlas to investigate tumour associated macrophages as regulators of immunotherapy response. Nature Communications. 15(1). 5665–5665. 30 indexed citations

Sng, Christopher C.T., et al.. (2024). Untranslated regions (UTRs) are a potential novel source of neoantigens for personalised immunotherapy. Frontiers in Immunology. 15. 1347542–1347542. 1 indexed citations

Hiley, Crispin T., T. Ahmad, Matthew Krebs, et al.. (2023). LBA72 DARWIN II: Deciphering anti-tumour response and resistance to immunotherapy with intratumour heterogeneity in NSCLC. Annals of Oncology. 34. S1314–S1314.

Gálvez‐Cancino, Felipe, Ignacio Matos, Danwen Qian, et al.. (2023). Fcγ receptors and immunomodulatory antibodies in cancer. Nature reviews. Cancer. 24(1). 51–71. 40 indexed citations

10.

Ziff, Oliver J., Jacob Neeves, Jamie S. Mitchell, et al.. (2023). Integrated transcriptome landscape of ALS identifies genome instability linked to TDP-43 pathology. Nature Communications. 14(1). 2176–2176. 36 indexed citations

11.

Sokač, Mateo, Johanne Ahrenfeldt, Kevin Litchfield, et al.. (2022). Classifying cGAS-STING Activity Links Chromosomal Instability with Immunotherapy Response in Metastatic Bladder Cancer. Cancer Research Communications. 2(8). 762–771. 12 indexed citations

12.

Swanton, Charles, William Hill, Emilia L. Lim, et al.. (2022). LBA1 Mechanism of action and an actionable inflammatory axis for air pollution induced non-small cell lung cancer: Towards molecular cancer prevention. Annals of Oncology. 33. S1413–S1413. 30 indexed citations

13.

Hodzic, Ermin, Raunak Shrestha, Salem Malikić, et al.. (2020). Identification of conserved evolutionary trajectories in tumors. Bioinformatics. 36(Supplement_1). i427–i435. 9 indexed citations

14.

Mehrabadi, Farid Rashidi, Salem Malikić, Osnat Bartok, et al.. (2020). PhISCS-BnB: a fast branch and bound algorithm for the perfect tumor phylogeny reconstruction problem. Bioinformatics. 36(Supplement_1). i169–i176. 14 indexed citations

15.

Litchfield, Kevin, James L. Reading, Emilia L. Lim, et al.. (2020). Escape from nonsense-mediated decay associates with anti-tumor immunogenicity. Nature Communications. 11(1). 3800–3800. 68 indexed citations

16.

Schnidrig, Désirée, Samra Turajlic, & Kevin Litchfield. (2019). Tumour mutational burden: primary versus metastatic tissue creates systematic bias. Immuno-Oncology Technology. 4. 8–14. 27 indexed citations

17.

Loveday, Chey, Amit Sud, Kevin Litchfield, et al.. (2019). Runs of homozygosity and testicular cancer risk. Andrology. 7(4). 555–564. 4 indexed citations

18.

Litchfield, Kevin, Chey Loveday, Max Levy, et al.. (2018). Large-scale Sequencing of Testicular Germ Cell Tumour (TGCT) Cases Excludes Major TGCT Predisposition Gene. European Urology. 73(6). 828–831. 44 indexed citations

19.

Levy, Max, Diana Hall, Amit Sud, et al.. (2017). Mendelian randomisation analysis provides no evidence for a relationship between adult height and testicular cancer risk. Andrology. 5(5). 914–922. 4 indexed citations

20.

Frampton, Matthew, Philip Law, Kevin Litchfield, et al.. (2015). Implications of polygenic risk for personalised colorectal cancer screening. Annals of Oncology. 27(3). 429–434. 51 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact